All In MedTech

FDA Clearance Tracker · P150038-S006

ExAblate

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 16, 2018

Approved

Time to decision

284 days

Received Mar 7, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150038-S006
Device name
ExAblate
Applicant
Insightec
Applicant location
Tirat Carmel
Received
Mar 7, 2018
Decided
Dec 16, 2018
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150038

Device type

Device class
Class III

Every decision under product code POH

FDA's approval statement

As written in FDA's record.

Approval for the Exablate Model 4000 (Neuro). The device is intended in the unilateral Thalamotomy (ventralis intermedius) treatment of Tremor-dominant Parkinson’s Disease with medication-refractory tremor. Patients must be at least age 30.

Source documents

Other decisions for Insightec

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.